Invivyd Inc. (NASDAQ: IVVD) initiated its DECLARATION clinical trial, a phase 3 study evaluating VYD2311, a monoclonal antibody candidate designed ...

This is a premium only article. To continue reading this and other premium stock market news articles please sign-in or upgrade to StreetInsider.com Premium below (Free Trial) LEARN MORE